• Price (EUR)44.60
  • Today's Change0.35 / 0.79%
  • Shares traded50.90k
  • 1 Year change-36.29%
  • Beta-0.0628
Data delayed at least 15 minutes, as of Mar 30 2023 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.

  • Revenue in EUR (TTM)196.34m
  • Net income in EUR49.36m
  • Incorporated1986
  • Employees515.00
  • Location
    Pharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
  • Phone+34 918466000
  • Fax+34 918466001
  • Websitehttps://www.pharmamar.com/es/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Calliditas Therapeutics AB71.24m-36.58m648.15m169.00--8.59--9.10-7.81-7.8115.1414.280.47056.7016.05---24.16-27.85-27.93-30.9598.11---51.35-125.044.33--0.4875--250.07--17.59------
Valneva SE361.30m-143.28m650.92m700.00--2.96--1.80-1.24-1.243.301.590.50234.0810.64---19.92-12.90-36.17-20.2610.2038.81-39.66-26.401.40-3.620.4094--3.8027.97-95.14--48.66--
Basilea Pharmaceutica AG148.32m12.19m653.98m141.0048.85--49.184.411.021.0212.46-1.730.63131.052.291,047,979.005.19-4.9911.10-7.6883.3583.798.22-
Boiron SA522.03m50.59m698.31m2.79k13.761.3011.951.342.892.8929.9030.670.69381.717.11188,527.306.715.968.457.5070.0676.849.678.412.28--0.045346.86-11.37-5.828.95-18.15-10.06-9.90
Puretech Health PLC17.14m-12.46m700.30m95.00--1.35--40.87-0.038-0.0380.05251.640.0216--4.76158,882.00-1.004.86-1.266.24-----46.43260.53----0.07710.0047.7631.45-1,111.83--9.02--
Surgical Science Sweden AB71.21m16.68m720.78m233.0043.311.9233.9110.123.693.6915.7683.390.1862.195.59--4.364.044.654.3266.2370.6723.4220.672.26--0.02470.00118.8169.51117.95--32.87--
Gen Ilac ve Saglik Urunleri Sanayi ve262.35m52.06m729.91m542.0014.025.4213.212.783.603.6018.169.311.888.2917.11--37.52--50.51--20.95--19.99--2.24--0.101--117.69--247.58------
Pharma Mar SA196.34m49.36m812.20m515.0016.213.5914.704.142.732.7310.8712.310.51560.71264.89381,248.5012.9619.9117.0828.8793.0593.9425.1428.432.5468.890.1605---14.574.33-46.85--13.67--
BioGaia AB97.96m33.17m813.63m212.0025.474.8323.068.313.703.7010.9319.530.50852.468.865,207,345.0017.2217.0218.4618.9172.6473.6033.8627.7710.03--0.005674.2040.6112.4190.4415.66-7.6210.01
Pharming Group N.V.189.63m12.61m824.37m321.0078.224.3733.284.350.01610.01610.27210.28750.49960.50447.14--3.328.433.8211.1691.4688.366.6514.243.941.670.4489--3.3915.26-14.52---11.60--
EIS Eczcb Ilc Sn ve Fn Ytm Sny ve Tct AS88.20m201.28m931.69m1.16k4.631.034.5510.566.106.102.6727.360.10992.585.561,582,207.0025.0715.3626.5516.3036.2734.58228.23113.931.42--0.0945--65.8925.08230.6397.4282.99--
Euroapi SAS943.90m2.00m947.86m3.34k632.490.847811.761.000.01590.015910.3011.83----------------16.44--0.2225--1.0511.330.0363--9.87--5.06------
AddLife AB806.04m42.59m957.75m2.20k23.242.258.961.193.943.9474.5940.780.76813.996.57--
FAES Farma SA438.75m89.55m972.75m1.77k10.651.598.942.220.29380.29381.441.960.64021.413.87248,445.1013.0613.0414.9915.3864.2563.4920.4019.022.10--0.0515--10.099.838.6916.7037.20--
Cosmo Pharmaceuticals NV102.05m17.22m976.18m295.0053.051.9831.149.571.041.046.1927.980.13053.293.24344,619.802.24-0.34782.62-0.369960.3458.4017.15-3.161.518.080.2724--56.888.71-20.52---19.80--
Vetoquinol SA536.71m48.07m1.01bn2.55k20.822.1612.271.874.064.0645.3639.240.8752.345.43210,803.207.826.9710.289.1849.2561.108.948.781.151,370.760.040815.1521.948.27227.0417.7018.9713.22
Data as of Mar 30 2023. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR

Institutional shareholders

7.45%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 03 Mar 2023381.44k2.06%
Norges Bank Investment Managementas of 31 Dec 2022261.81k1.41%
BlackRock Fund Advisorsas of 01 Mar 2023204.66k1.10%
Santander Asset Management SA SGIICas of 30 Sep 2022109.54k0.59%
Dimensional Fund Advisors LPas of 02 Mar 2023107.04k0.58%
BlackRock Advisors (UK) Ltd.as of 01 Mar 202371.71k0.39%
Jupiter Asset Management Ltd.as of 30 Nov 202263.91k0.34%
Credit Suisse AGas of 31 Jan 202362.62k0.34%
TIAA-CREF Investment Management LLCas of 31 Jan 202361.60k0.33%
Teachers Advisors LLCas of 31 Jan 202357.44k0.31%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.